Jefferies flags disappointing Phase 2 eye-drop results for KHK4951
Jefferies says Kyowa Kirin’s latest Phase 2 clinical data for ophthalmology eye drops candidate KHK4951 is disappointing, materially weakening a key pipeline opportunity.
Jefferies analysts say Kyowa Kirin’s latest clinical data for an ophthalmology drug candidate are disappointing. The bank says Phase 2 clinical results for KHK4951 eye drops materially weaken one of Kyowa Kirin’s important pipeline opportunities. Kyowa Kirin said Tuesday the study f…